---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274192"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:50:28.192757+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q3 2025: Net loss $13.1M, China sale ~$220M, cash $121.1M into 2028

## Summary
- Net loss from continuing ops $13.1M ($3.25 loss per share) vs $48.3M ($12.01 loss) YoY.
- Total revenue from continuing ops $1.1M, up from $0.1M YoY.
- Completed sale of FibroGen China to AstraZeneca for ~$220M ($85M enterprise + $135M net cash).
- Cash, equivalents, receivables, and investments $121.1M; cash runway into 2028; repaid Morgan Stanley term loan.
- Initiated Phase 2 trial of FG-3246 in mCRPC; FDA agreed on Phase 3 roxadustat design for LR-MDS.

## SEC filing metadata
- accession: 0001193125-25-274192
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/0001193125-25-274192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274192
- JSON: https://secwatch.observer/filing/0001193125-25-274192.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.